4baseCare Founders L to R Kshitij Rishi and Hitesh GoswamiPrecision oncology startup 4baseCare has raised ₹90 crore in the first close of its Series B funding round, co-led by investors Ashish Kacholia and Lashit Sanghvi, with participation from existing backer Yali Capital.
The Bengaluru-based company plans to use the capital to expand its hospital-linked genomics lab network across India, the Middle East, Southeast Asia, Latin America, and Central Asia, and to scale its AI-based precision oncology platform, OncoTwin.
“This funding will help us scale globally while building OncoTwin as an AI-driven decision support platform that learns from real-world clinico-genomic outcomes and supports oncologists with faster, more confident insights,” said Hitesh Goswami, CEO of 4baseCare.
The startup focuses on enabling inclusive access to precision cancer care, particularly in emerging markets.
“4baseCare is building a powerful genomics and AI-driven clinical intelligence platform for inclusive precision oncology. With strong hospital partnerships enabling access to world-class diagnostics for patients in clinical settings, the company is well positioned to scale across emerging markets and expand its delivery model for maximum patient benefit,” said Kacholia and Sanghvi, in a joint statement.
The company had earlier raised ₹50 crore in Series A funding, led by Yali Capital, with participation from Infosys.
As part of its product roadmap, 4baseCare will fuel the deployment of OncoTwin Insights, its AI-driven clinical decision support solution that helps oncologists to gain insights from real-world clinico-genomic and outcomes-linked datasets.
Currently, 4baseCare works with hospitals and clinicians to combine genomic testing with AI-led insights, to improve treatment outcomes for underrepresented patient populations.
Leave a Reply